Systems and methods for pre-analytical substrate processing
Granted: November 7, 2023
Patent Number:
11807900
Some embodiments presented in this disclosure concern an Automated Tissue Dissection (ATD) System. An ATD system is a one stop, and potentially low-cost, system to perform dissections on a substrate from pathologist digital mark or pen mark on the substrate using non-contact and/or mechanical method to extract a Formalin-Fixed Paraffin-Embedded (FFPE) tissue sample with: (a) only the ROI or ROIs as area to be saved; and (b) remove or decompose nucleic acid content in the region of no…
Method to use gene expression to determine likelihood of clinical outcome of renal cancer
Granted: October 3, 2023
Patent Number:
11776664
The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
DNA methylation and mutational analysis methods for bladder cancer surveillance
Granted: May 16, 2023
Patent Number:
11649506
The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
Granted: January 10, 2023
Patent Number:
11551782
The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the…
Gene expression markers for breast cancer prognosis
Granted: January 11, 2022
Patent Number:
11220715
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
Methods for depleting RNA from nucleic acid samples
Granted: October 19, 2021
Patent Number:
11149297
The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
Gene expression profile algorithm and test for determining prognosis of prostate cancer
Granted: May 18, 2021
Patent Number:
11011252
The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
Method to use gene expression to determine likelihood of clinical outcome of renal cancer
Granted: January 12, 2021
Patent Number:
10892038
The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
Prediction of likelihood of cancer recurrence
Granted: April 14, 2020
Patent Number:
10619215
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
Method for using gene expression to determine prognosis of prostate cancer
Granted: April 16, 2019
Patent Number:
10260104
The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
Gene expression profiling in biopsied tumor tissues
Granted: March 26, 2019
Patent Number:
10241114
The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.
Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
Granted: January 15, 2019
Patent Number:
10181008
The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the…
Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
Granted: January 15, 2019
Patent Number:
10179936
Algorithm-based molecular assays that involve measurement of expression levels of prognostic and/or predictive genes, or co-expressed genes thereof, from a biological sample obtained from a cancer patient, and analysis of the measured expression levels to provide information concerning the likelihood of recurrence of colorectal cancer and/or the likelihood of a beneficial response to chemotherapy for the patient are provided herein. Methods of analysis of gene expression values of…
Gene fusions and alternatively spliced junctions associated with breast cancer
Granted: January 1, 2019
Patent Number:
10169530
The present invention relates to gene fusions and alternative spliced junctions associated with breast cancer. The present invention also relates to novel methods of identifying gene fusions and alternative spliced junctions in RNA sequencing data. The present invention further relates to predicting prognosis of a breast cancer patient based on the number of gene fusion events.
Gene expression markers for breast cancer prognosis
Granted: April 17, 2018
Patent Number:
9944990
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
Methods for depleting RNA from nucleic acid samples
Granted: February 27, 2018
Patent Number:
9902991
The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
Gene expression markers for predicting response to chemotherapy
Granted: March 28, 2017
Patent Number:
9605318
The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1;…
Method to use gene expression to determine likelihood of clinical outcome of renal cancer
Granted: January 24, 2017
Patent Number:
9551034
The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
Methods for depleting RNA from nucleic acid samples
Granted: April 14, 2015
Patent Number:
9005891
The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
Genes involved in estrogen metabolism
Granted: December 9, 2014
Patent Number:
8906625
The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.
